A
Acornmed
The world's leading provider of tumor molecular diagnosis and scientific research transformation services
About Acornmed
Acornmed, officially known as AcornMed Biotechnology Co., Ltd., is a precision medicine company established in 2018 with headquarters in Beijing, China. The company was co-founded by Chairman Dr. Shanbo Cao and CTO Dr. Feng Lou. Dr. Cao holds a Ph.D. from the University of Hong Kong and possesses extensive experience in clinical medical translation and operational management. Dr. Lou earned a Ph.D. in bioinformatics from Paris-Sud University and is recognized for his significant contributions to the field of liquid biopsy in China. The firm was incubated at Peking University, reflecting its strong scientific research foundation.
Acornmed operates in the precision oncology market, providing genomic testing solutions and services. Its business is structured into three main segments: early screening, diagnosis, and monitoring of cancer; medical testing for cancer patients; and collaborative research and development with pharmaceutical companies. The company serves both physicians and patients, offering a portfolio of over 30 testing products that cover hereditary cancer identification, companion diagnostics for targeted and immunotherapy, and longitudinal tumor monitoring. Revenue is generated through the sale of its testing products and services to a network of over 500 hospitals.
The company's core offering is a suite of non-invasive genomic tests based on its proprietary biomarker discovery platform and next-generation sequencing (NGS) technology. Key products include the AcornUI series for urothelial carcinoma and the AcornUPro-SEEK test for prostate cancer, both of which utilize urine samples for detection and monitoring. For solid tumors and hematologic malignancies, it offers tests like AcornOne 808 and AcornHema 521. A significant milestone was the 2024 NMPA approval for its Early Detection Kit for Urothelial Carcinoma. The company has established R&D and testing centers in Beijing and Tianjin. To date, Acornmed has raised a total of $44 million in funding, with its Series B round concluding in July 2022.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Haidian, China
- Employees
- 7
- Open positions
- 10
- Dealroom signal
- 36.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2022 | $28M | $110M | Qingdao Hongteng Equity Investment · Lichen Investment · Yikai Venture Capital · Pragmatic capital | ↗ |
| OtherOther financing | Apr 2020 | $0 | — | Sino-Ocean Group | — |
Growth signals
Latest recorded traffic for Acornmed is 230 monthly website visits, down 70.1% over the last three months. Acornmed's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- QIQingdao Hongteng Equity Investment
- LILichen Investment
- YCYikai Venture Capital
Pragmatic capital
Other known investors1 additional known investor
- SGSino-Ocean Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acornmed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acornmed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.